ClinicalTrials.gg
Not yet recruitingNCT07856719Updated Oct 5, 2026

A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy

A Phase 2 interventional study of Colchicine and Placebo in Head and Neck Cancer, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Supportive care

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center — 8 open to participants now, 21 under way, 1 of them phase 3. Head and Neck Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
7th of 56
250 · median 25
Started
2027
with 1 other
Phase 2
19 of 74
3 open now
Primary completion
2032-07
later than 20 of 20 live
Registered
74th of 74
by date

Among the 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center, this one is the 7th largest by planned enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2027, is one of 19 in phase 2, reaches primary completion later than 20 of the 20 other live ones, and was the 74th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

8 of the 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Head and Neck Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

The goal of this clinical research study is to find out if low-dose colchicine (an anti-inflammatory drug) lowers the rate of radiation-related side effects to the carotid artery in patients who have completed radiation therapy for head and neck cancer.

Read the detailed description

Primary Objective:

To evaluate whether low-dose colchicine (0.6 mg orally once daily for 24 months) reduces radiation-induced carotid vascular injury compared to placebo in survivors of head and neck cancer who have completed curative-intent radiotherapy, as assessed by a hierarchical composite endpoint analyzed using the win ratio method, comprising: (1) time to death; (2) time to TIA, CVA, or ischemic heart disease; (3) time to carotid artery stenosis >50%; and (4) change in carotid intima-media thickness (CIMT) from pre-radiotherapy baseline to 24 months postrandomization.

Secondary Objective:

Efficacy

  1. To evaluate the effect of colchicine on each individual component of the primary hierarchical composite endpoint.
  2. To assess carotid plaque development, progression, and regression by serial duplex ultrasound.
  3. To characterize longitudinal CIMT trajectory from pre-radiotherapy baseline through the 24-month intervention period using all available imaging timepoints.
  4. To evaluate carotid artery volume change from pre-radiotherapy baseline to month 24.

    Safety and tolerability

  5. To evaluate the safety and tolerability of low-dose colchicine in HNC survivors, with adverse events graded per CTCAE v6.0.
  6. To assess study medication adherence.
  7. To assess the rate of locoregional and distant cancer recurrence during the study period.

    Exploratory and correlative

  8. To determine whether baseline SASP-related circulating biomarkers (GAGome, serum glutamate, H₂S) and CHIP status predict RICAD risk and treatment response to colchicine.
  9. To evaluate ALDH2 expression and 4-HNE adduct levels in PBMCs as pharmacodynamic markers of colchicine target engagement.
  10. To assess whether the baseline NAA index refines RICAD risk stratification beyond traditional cardiovascular risk factors.
  11. To develop a clinical decision support tool integrating baseline clinical characteristics, 3D dosimetry, and carotid imaging to predict adverse carotid outcomes following RT.
03

Conditions studied

  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18 years.
  • Clinical diagnosis of head and neck cancer (HNC), including of the oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, or salivary glands.
  • Receipt of curative-intent radiotherapy to the neck, completed ≤18 months prior to randomization.
  • No evidence of locoregional or distant disease recurrence, confirmed by standard-of-care imaging at 3-6 months post-RT completion as documented by the treating head and neck radiation oncologist. Participants must not be scheduled to receive additional cancerdirected systemic or radiation therapy during the study period.
  • performance status ≤2.
  • For women of (WOCBP): negative serum or urine pregnancy test within 7 days prior to randomization and agreement to use adequate for the duration of study treatment and for at least 30 days following the last dose of study drug. WOCBP is defined as any female between the onset of menses and 55 years of age unless an applicable exclusionary factor is present ( ≥12 consecutive months without menses; history of hysterectomy or bilateral salpingo-oophorectomy; history of bilateral tubal ligation or other surgical sterilization). Approved methods of contraception include hormonal contraception (oral, injectable, implantable, transdermal, or vaginal ring), intrauterine device (IUD), and barrier methods (condom plus spermicide). Periodic abstinence and the rhythm method are not acceptable. (Refer to MD Anderson Institutional Policy #CLN1114.) Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Male participants must agree to use adequate contraception for the duration of study treatment, given the potential effects of colchicine on spermatogenesis through microtubule inhibition.
  • Ability to understand and willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Palliative or non-curative intent radiotherapy.
  • Known carotid artery stenosis ≥50% at baseline screening.
  • Prior history of radiotherapy to the neck (other than the qualifying course of RT for this study), carotid artery dissection, or prior carotid revascularization (endarterectomy or stenting).
  • Known or prior intolerance to colchicine.
  • Current chronic use of colchicine for any other indication.
  • Severe renal impairment ( \<30 mL/min/1.73 m² by CKD-EPI equation) or end-stage renal disease requiring dialysis.
  • Severe hepatic impairment (Child-Turcotte-Pugh class C).
  • Pre-existing significant blood dyscrasia, defined as \<1,500 cells/mm³ or count \<50,000 cells/mm³.
  • Concurrent requirement for strong inhibitors (e.g., clarithromycin, itraconazole, cyclosporine) or P-glycoprotein (P-gp) inhibitors that cannot be discontinued for the duration of study treatment. A list of prohibited concomitant medications is provided in Appendix A.
  • History of peripheral neuritis, myositis, or myopathy attributed to statin therapy.
  • Chronic systemic use for any ongoing medical condition.
  • Pregnancy, breastfeeding, or expressed intent to become pregnant during the study period.
  • Concurrent enrollment in another clinical trial with an active interventional treatment arm.
  • Psychiatric illness or social circumstances that would limit compliance with study requirements or follow-up.
  • Any condition that, in the opinion of the investigator, would prevent protocol adherence or compromise participant safety
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Double- blind Treatment with Colchicine or Placebo

    Treatment will be administeredon an outpatient basis

    Drug: Colchicine · Other: Placebo

Interventions

  • 0.6 mg given by mouth once daily for 24 months

    Also known as: Colcrys, Mitigare, Gloperba, Lodoco

  • OtherPlacebo

    Given by mouth once daily for 24 months

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Jul 2032, 64 months later.

Of 219 non-industry phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's planned 64 months is above that.

Counting every sponsor, half of 263 studies reached it within 51 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Jul 1, 2032
CompletionEst.
Jul 1, 2034
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856719
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Jul 1, 2032 (estimated)
Completion
Jul 1, 2034 (estimated)
Last update
Oct 5, 2026

Study contacts

Efstratios Koutroumpakis, MD
Contact
ekoutroumpakis@mdanderson.org
(713) 563-5439
Efstratios Koutroumpakis, MD
principal investigator · UT MD Anderson

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion